Hsp90 as a therapeutic target in patients with oesophageal carcinoma (Q37690758)

22 August 2017

1 reference

title

Hsp90 as a therapeutic target in patients with oesophageal carcinoma (English)

1 reference

22 August 2017

Simon Ekman

1

1 reference

22 August 2017

Michael Bergqvist

2

1 reference

22 August 2017

Roger Tell

3

1 reference

22 August 2017

Stefan Bergström

4

1 reference

22 August 2017

Johan Lennartsson

5

1 reference

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

Expert Opinion on Therapeutic Targets

22 August 2017

published in

1 reference

22 August 2017

volume

14

1 reference

22 August 2017

issue

3

1 reference

22 August 2017

page(s)

317-328

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

22 August 2017

1 reference

Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

First-line therapy for chronic myeloid leukemia: Past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Structural and functional coupling of Hsp90- and Sgt1-centred multi-protein complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Chaperoned ubiquitylation--crystal structures of the CHIP U box E3 ubiquitin ligase and a CHIP-Ubc13-Uev1a complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Structural Analysis of E. coli hsp90 reveals dramatic nucleotide-dependent conformational rearrangements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Stimulation of the weak ATPase activity of human hsp90 by a client protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Regulation of Hsp90 ATPase activity by the co-chaperone Cdc37p/p50cdc37.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

An acetylation site in the middle domain of Hsp90 regulates chaperone function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Release of heat shock proteins from human neuroblastoma cells exposed to acrylamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Involvement of cell surface HSP90 in cell migration reveals a novel role in the developing nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Functional proteomic screens reveal an essential extracellular role for hsp90 alpha in cancer cell invasiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

A critical role for HSP90 in cancer cell invasion involves interaction with the extracellular domain of HER-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Critical regulation of TGFbeta signaling by Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Modulation of Akt kinase activity by binding to Hsp90

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Cdc37 is a molecular chaperone with specific functions in signal transduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Structure of an Hsp90-Cdc37-Cdk4 complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

P-Glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Formation of 17-allylamino-demethoxygeldanamycin (17-AAG) hydroquinone by NAD(P)H:quinone oxidoreductase 1: role of 17-AAG hydroquinone in heat shock protein 90 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Unusual expression and localization of heat-shock proteins in human tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Hsp90: a novel target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Toward noninvasive genomic screening of lung cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Antimyeloma activity of heat shock protein-90 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Heat shock protein 90 as a molecular target for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Differential expression of the MAD2, BUB1 and HSP27 genes in Barrett's oesophagus-their association with aneuploidy and neoplastic progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Expression of heat-shock protein Hsp60 correlated with the apoptotic index and patient prognosis in human oesophageal squamous cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Potentiation of chemotherapeutics by the Hsp90 antagonist geldanamycin requires a steady serum condition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Overexpression and localization of heat shock proteins mRNA in pancreatic carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

High HSP90 expression is associated with decreased survival in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Heat shock proteins HSP27, HSP60, HSP70, and HSP90: expression in bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Heat shock protein 90 overexpression independently predicts inferior disease-free survival with differential expression of the alpha and beta isoforms in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Preferential sensitization of tumor cells to radiation by heat shock protein 90 inhibitor geldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Epidemiology and pathogenesis of esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

Cancer robustness: Tumour tactics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728221003621278

10.1517/14728221003621278

21 January 2018

Identifiers

DOI

1 reference

22 August 2017

1 reference